Cleveland Clinic Cancer Advances
A Cleveland Clinic podcast for medical professionals exploring the latest innovative research and clinical advances in the field of oncology.
Cleveland Clinic Cancer Advances
Insights from the RedirecTT-1 Study: A Potential Game-Changer for R/R Myeloma with EMD
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Shahzad Raza, MD, Hematologist at Cleveland Clinic, joins the Cancer Advances podcast to share insights from the RedirecTT-1 study. This study, presented at the 2025 American Society of Hematology (ASH) Annual Meeting, explores combining two bispecific antibodies, talquetamab and teclistamab, for patients with relapsed/refractory multiple myeloma with extramedullary disease. Listen as Dr. Raza discusses disease biology, outcomes, safety considerations and why this approach could be a major step forward for high-risk myeloma care.